January 25, 2021
Second Genome has announced the appointment of Susannah Cantrell, PhD, to the position of chief business officer, and Preeti G. Lal, Ph.D., to the position of chief scientific officer.
Susannah Cantrell, Ph.D., joined Second Genome as chief business officer in November 2020. Dr. Cantrell has over 20 years of industry experience across global pipeline strategy, sales, operations, marketing, and new product commercialization. Her experience covers multiple therapeutic areas including cell therapy, oncology, inflammation, anti-infectives, cardiology, neurology, nephrology, and endocrinology. She most recently served as EVP and chief commercial officer at Tricida and prior to that was vice president and head of global commercial strategy and marketing oncology at Gilead Sciences where she was instrumental in leading and building its oncology and inflammation business from 2011 to 2019.
Prior to her time at Gilead, Dr. Cantrell held various senior-level positions at Genentech/Roche from 2005 to 2011, including marketing, strategic business planning, and sales. She participated in life-cycle management and the pre-launch and commercial launch of several products, including RITUXAN, HERCEPTIN, AVASTIN, and TARCEVA. Prior to Genentech, Dr. Cantrell held sales and marketing positions at GlaxoSmithKline, where she managed the anti-infective portfolio. Dr. Cantrell holds a BA in Biology from Westminster College and a PhD in Biochemistry from the University of Missouri-Columbia.
Preeti G. Lal, Ph.D., joined Second Genome in 2021 as chief scientific officer. She also serves on the Scientific Advisory Board of Alladapt Immunotherapeutics. Dr. Lal has over 25 years of experience leading data science, translational medicine activities in all phases of clinical trials, regulatory interactions with both the drug and device divisions of FDA and companion diagnostics programs. Prior to Second Genome, she worked at several leading healthcare companies including Alladapt Immunotherapeutics, Roche Diagnostics, Gilead Sciences, Genentech, and CareDx.
At CareDx, she leveraged data science, bioinformatics, and immunology to develop the multigene diagnostic algorithm “AlloMap” which is an FDA approved diagnostic test in clinical use for the management of heart transplant subjects leading to reduction in the number of routine heart biopsies. Following her Ph.D., she spent seven years at Incyte Genomics where she worked on numerous pharma collaborations as the bioinformatics technical lead. Dr. Lal is a co-inventor on over 150 patents. She obtained her PhD in Immunology from the Medical University of South Carolina and MSc (Hons) in Microbiology from Bombay University, India. She did her fellowship in Tumor Biology at Stanford University where she worked on the role of GFAP in Astrocytoma.
“I am delighted to welcome both Susannah and Preeti to the Second Genome executive team. Their vast experience in life sciences and leadership will be critical in driving Second Genome’s strategy and pipeline as we evolve into a product development company,” stated Karim Dabbagh, Ph.D., president, and chief executive officer at Second Genome. “The tremendous potential for innovation in drug development to arise from our microbiome science-based platform is a driver of an exciting plan to develop personalized therapies for multiple diseases and to partner our technology broadly across the industry, so we are excited to have Susannah and Preeti join our team at this point in our journey.”